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During the recent past, the scientific community
has been concerned with the effects of environmen-
tal pollutants on man and other animals. For the
most part, the pollutants of interest have been man-
made chemicals added inadvertently to the environ-
ment through waste disposal, over energetic use,
and so on, or deliberately for some presumed
worthwhile reason. There is little doubt that these
contaminants represent potentially severe health
hazards. There also exist in our ecosphere, how-
ever, other potential health hazards not provided by
man's ingenuity or carelessness.
The mycotoxins are a diverse group of chemicals
produced by an equally diverse group of fungi. The
beneficial effects of the penicillins, produced by
several species of Penicillia, are well known.
Equally important, however, is a broad range of
chemical substances produced by fungi that are
hazardous to man and other animals. A number of
such substances have been demonstrated [1, 2], but
probably the aflatoxins are the most notorious of
the fungal toxins in modern times. These com-
pounds produce not only acute toxic syndromes,
but also are carcinogenic [3]. The cancer-produc-
ing capability of the afiatoxins has been demon-
strated in laboratory animals and is suggested from
epidemiologic data to occur in man. Other myco-
toxins may be potentially just as dangerous,
however. For example, the rubratoxins can alter
hepatic function and are teratogenic; penicillic
acid may have toxic effects on the cardiovascular
system in laboratory animals; and several fungal
metabolites are nephrotoxic (see below).
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Citrinin (Fig. 1), produced by Penicilliurn citrin-
urn, P. veridicatum, etc., is well established as a
nephrotoxic fungal product [4]. Ochratoxin A (Fig.
1) also has been suggested to be nephrotoxic [5, 6].
Although there is some debate as to the nephrotoxic
activity of ochratoxin A in all species, there is
little doubt that it can produce alterations in renal
function [7]. In any event, both ochratoxin A and
citrinin have been found in association with neph-
rotoxicity in animals that ingested contaminated
grain [6]. Further, regardless of the specific toxin
or toxins involved, Krogh has argued effectively
that mycotoxin-induced nephropathy might serve
as a realistic model for various nephropathies, for
example, the human disease Balkan nephropathy
[8].
One or both of these toxins has been associated
with porcine nephropathy [5, 6]. This disease has
been produced in pigs either by feeding grain con-
taminated with toxin-producing mold, feeding the
mold directly, or by the administration of citrinin or
ochratoxin A, or both. Some of the characteristics
of this disease and possibly related nephropathies
are summarized in Table 1. There is little doubt con-
cerning the cause-and-effect relationship of fungal
toxins to porcine nephropathy and probably to simi-
lar nephropathies observed in horses and birds [9].
The Balkan nephropathy, which occurs in people
who reside in certain areas of the Danube River ba-
sin in the Balkan countries, also may be the con-
sequence of ingestion of fungal toxins [10]. For ex-
ample, it has been possible to demonstrate the pres-
ence of ochratoxin A in food samples taken from
the homes of individuals affected with the disease.
Also, ochratoxin A has been demonstrated in blood
samples from humans in an endemic area of Yugo-
slavia [11]. Citrinin, on the other hand, has been
suggested only as a possible contributor to this hu-
man disease state [12]. Some of the characteristics
of this disease are listed in Table 2 and are com-
pared with other nephropathies in Table 1. The re-
nal failure syndrome, although not identical to that
seen in porcine nephropathy, is similar.
Because of the difficulties involved in field studies
in general and especially for studies on mecha-
Table 1. Comparison of avian, Balkan, porcine, and rat
nephropathy
Nephropathya
Avian Balkan Porcine Rat
Urine parameters:
Polyuria I I I I
Glucosuria ND I I I
Proteinuria I I I I
Osmolality , , ,
Renal function:
GFR
CFAH 1, ' J'
BUN ND I I
Proximal tubular
Histopathologic + + + +
In vitro ND ND + +
Etiology was avian, ochratoxin A; Balkan, unknown; por-
cine, ochratoxin A and/or citrinin; rat, citrinin.
Table 2. Balkan nephropathy
Endemic:
Near Danube
Region of high humidity and rainfall
Rural setting
Newcomers unaffected:
30 to 60 years of age
Nutrition, general hygiene, socioeconomic status not factors
Renal effects:
Progressive tubular destruction with interstitial and capsular
fibrosis
Gross renal atrophy resultsa
Lower" proximal tubule involved along with loop of Henle
Glomerular changes?—Perhaps secondary to tubular
damage
Defects in acidification and NH3 excretion
PAH clearance reduced
Glucose excretion increased
GFR decreased
Gross proteinuria
About one third of dying patients have papillomas and/or car-
cinomas of renal pelvis, ureters, or bladder.
nisms, a reproducible laboratory animal model use-
ful for controlled studies of mycotoxic nephropathy
was developed [4, 7]. With the Sprague-Dawley rat,
it was possible to demonstrate that both citrinin and
ochratoxin A can alter renal function and to exam-
ine underlying causes of these alterations. Barnes et
al [13] also found the rat model useful and tested the
effects of various mold homogenates in a force-
feeding protocol.
Rat Model. An approach to the validation of the
rat model for the study of naturally occurring neph-
rotoxic substances is to compare data obtained in
the model studies with those found in the field, for
example, a correlation of the rat studies with what
has been reported for the pig (Table 1). In earlier
studies by Berndt and Hayes [4], rats were injected
with single or repeated doses of citrinin. Renal func-
tion was monitored over several days after treat-
ment, and these data were similar if not identical to
those reported from field experiences. Enhanced
excretion of urine with low osmolality was seen,
and this effect was sustained for several days even
after a single administration of citrinin. In addition,
urinary excretion of protein and glucose was en-
hanced. Citrinin also interfered with the ability of
the rat kidney to transport a variety of model com-
pounds known to be prototypical for various renal
transport systems [14]. p -Aminohippurate (PAH),
an organic anion, was transported less well by rat
renal cortex slices removed from rats pretreated
with citrinin than it was by control tissue. Similar
but less dramatic effects were seen with organic cat-
ions such as N-methylnicotinimide (NMN) and tet-
raethylammonium (TEA). Except for one study
with ochratoxin A on the tubular transport maxi-
mum for PAH in pigs [15], specific studies on renal
transport by pig tissue have not been undertaken, at
least in the context of an analysis of mycotoxin ne-
phropathy.
Overall, it appears that a positive correlation ex-
ists between the renal behavior in field outbreaks of
mycotoxicoses and those produced by the adminis-
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Fig. 1. Molecular structure of ochratoxin A and citrinin.
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tration of citrinin or ochratoxin A in controlled lab-
oratory experiments. Because of this correlation,
relatively straightforward laboratory studies can be
undertaken that will have predictive value for simi-
lar intoxications in addition to offering techniques
and procedures for an evaluation of fundamental
mechanisms of nephrotoxicity.
Effects of mycotoxins on the kidney
Morphology. A number of studies have been un-
dertaken wherein possible alterations of renal struc-
ture in response to mycotoxins have been exam-
ined. Early reports by Larson [16], Ambrose and
DeEds [17], and others [18, 19] indicated that after
ingestion of moldy grain or administration of citri-
nm, kidneys were gray in color and had granular
surfaces. Apparently the medullary regions of the
kidneys were engorged with blood whereas the cor-
tical regions were blanched. Studies in the mouse
and dog by Canton, Szczech, and Tuite [18] and
Jordan, Carlton, and Sansing [19] suggested the oc-
currence of a distal tubular lesion. Proximal tubular
effects were observed but apparently only with
large doses of nephrotoxin and only after distal
tubular structural changes had been seen. Studies
done in our laboratory (Phillips et al, in preparation)
suggest the primary lesion to be in the proximal
convoluted tubule in the rat, and not distally. Light
microscopic studies showed proximal tubular ne-
crosis, indicative of the classical acute tubular ne-
crosis associated with many recognized nephrotox-
ins, for example, heavy metals, organic solvents,
and so on. Many investigators have reported that
such lesions occur regardless of the chemical type
of nephrotoxin involved, a result that has been sug-
gested to be consistent with a disruption of vascular
events within the kidney.
A recent electron microscopic study in the rat
[20] confirmed and expanded these original obser-
vations. This study documented that in the rat no
glomerular damage was observed after citrinin, nor
was there any involvement of the loop of Henle,
distal segments of the nephron, or collecting duct.
Only the proximal tubular cells, and in particular
those of the convoluted portion of the proximal tu-
bule, were affected. The proximal tubule brush bor-
der had disintegrated, and mitochondria were swol-
len and disorganized, as was the endoplasmic retic-
ulum. This pattern was not appreciably different
from necrotic phenomena observed with many
nephrotoxins.
Studies with other mycotoxins such as ochratox-
in A [15, 21] suggest sites of action that are similar,
if not identical to those for citrinin. Again, proximal
tubular involvement is most noteworthy, although
some uncertainties concerning other tubular actions
still exist.
Renal function. The studies by Krogh et al [15]
have shown that the pig is sensitive to ochratoxin A
fed in the diet. In these studies, which involved
feeding low levels of ochratoxin for long periods of
time, both GFR and RBF (PAH clearance) were de-
pressed. A more pronounced and earlier effect was
observed, however, on the tubular transport maxi-
mum of PAH than on glomerular filtration.
Although considerable morphologic data were
available, detailed renal function studies were not
done by Carlton et a! [18]. Preliminary renal func-
tion data, however, were indicative of renal failure
(for example, elevation of BUN). Details con-
cerning urinary volume, urine osmolality, and so
forth, were not presented.
Studies in the rat [4, 22, 23] suggested that citrinin
and possibly ochratoxin A are capable of producing
acute tubular necrosis with accompanying renal
failure. With citrinin in moderately effective doses,
the acute renal failure observed is of the "high out-
put" variety. Urine volume was observed to triple
within 24 hours of the injection of a single dose of
citrinin and to be sustained at the high level for
about 3 days. Urine osmolality was reduced signifi-
cantly, recovering toward normal only when the
urine volume fell. In concert with these observa-
tions was the enhanced urinary excretion of protein
and glucose (Fig. 2). In addition, the BUN rose sig-
nificantly in a dose-dependent manner.
Other responses of the rat to injected citrinin also
were unusual. Although a dose of 50 mg/kg pro-
duced a completely reversible renal lesion in the
majority of animals (all rats that survived 72 hours
after injection), about 30% of those treated died.
The moribund animals invariably developed anuria
and excreted large amounts of glucose in the urine
in the 24- to 36-hour period before death ensued.
Hence, it appeared as if the rat population respond-
ed in an all-or-none fashion to the anuric potential
of citrinin, and the rats so affected failed to recover.
Ochratoxin A also has been studied in the rat [7].
The pattern of response to this toxin was consid-
erably different from that for citrinin. Large, single
doses of ochratoxin A injected i.p. produced death
but without obvious alterations in renal function.
Low, single, nonlethal doses of ochratoxin A failed
to alter renal function or animal behavior. Small
doses (0.4 to 2.0 mg/kg) injected repeatedly (daily
for 4 to 8 days), however, produced changes in re-
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Fig. 2. Effects of citrinin on renal function in the male Sprague-
Dawley rat. Citrinin was injected after a 24-hr control period (ar-
row). Urine volume and osmolality were significantly different
from control on days I to 3 (P < 0.05). (Reprinted with per-
mission of J Environ Pathol Toxicol [4])
nal function, excessive weight loss, diarrhea, and if
continued, death. Unlike with citrinin, ochratoxin
A produced only a slight increase in urine flow, al-
though urine osmolality fell significantly. Relatively
modest increases in protein excretion were ob-
served, although urinary glucose and ketones rose
considerably. The most dramatic effect was the per-
sistent weight loss (Fig. 3). This pattern of response
(weight loss, glucose excretion, ketone excretion) is
suggestive of a diabetic state, but blood glucose
tended to fall over a 5-day period of daily injections
(2 mg/kg) of ochratoxin A.
The requirement for repeated doses of ochratoxin
A suggested the necessity for accumulation of the
toxin. Perhaps this was indicative of the necessity
0 - + + + + + + +
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Fig. 3. Effects of ochratoxin A on renal function in the intact
male, Sprague-Dawley rat. Each point is the mean value for N =
6. Ochratoxin A was injected i.p. on days 1 through 5. Significant
decreases in urine osmolality were seen on day 4 and thereafter.
(Reprinted with permission of Toxicology [7])
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for relatively high concentrations of ochratoxin A in
the rat before an effect was observed or that the tox-
in must be present continually at lower concentra-
tions for any effect to be seen. Such was not the
case with citrinin.
Pharmacokinetic studies with the 54C-labeled
compound and high-pressure liquid chromatograph-
ic (HPLC) techniques [23, 24] indicated that the la-
bel disappeared from the rat rapidly and that exten-
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sive metabolism of citrinin occurred. More than
70% of the label appeared in the urine and feces by
24 hours. In animals with normal renal function, as
little as 10 to 15% of the administered label ap-
peared in the feces, whereas in rats with poor renal
function more than half of the label was excreted by
the fecal route. Significant levels of a metabolite can
be identified in the blood of an anesthetized rat
within 10 mm of the administration of citrinin.
About 20 to 30% of the administered chemical ap-
pears as a metabolite in the urine 24 to 48 hours
after i.p. injection.
The relatively short biological half-lives of citri-
nm (2.5 and 14.9 hours) suggested that accumula-
tion of this compound was unlikely to occur. Fur-
ther, the rapidity with which citrinin and/or its me-
tabolites were excreted, coupled with the rapid
onset of nephrotoxicity, suggested that citrinin pro-
duced an effect that was sustained even after the
fungal toxin was eliminated. Indeed, even in an ani-
mal with compromised renal function, labeled citri-
nm still disappeared rapidly, although the routes of
elimination differed quantitatively from those in the
normal animal. For example, if the rat were pre-
treated 3 to 4 days prior to administration of the la-
beled citrinin with a nephrotoxic dose of the same
compound, more than 70% of the label disappeared
from the animal in the first 24 hours. Fully half of
this disappearance, however, now occurred by way
of the feces, with correspondingly less appearing in
the urine. Direct measurement of GFR in anesthe-
tized rats demonstrated values as low as one tenth
to one quarter that of normal (Phillips et al, in prep-
aration). The depression in GFR was dose-depen-
dent even in those animals with significantly in-
creased 24-hour urine volumes. Despite the ele-
vated daily urine output, the greatly reduced GFR
apparently accounted for poor elimination of citri-
nm in the urine. The decreased urinary elimination
was compensated for by enhanced fecal (probably
biliary) excretion.
In addition to effects on overall renal function in
the rat, effects on specific renal transport processes
also have been shown [4, 7]. In part, this was antici-
pated from the earlier work of Krogh et al [15],
wherein the clearance of PAH was reduced by och-
ratoxin A. With citrinin, effects on the transport of
PAH, as well as organic cations such as TEA or
NMN, were observed in renal slices taken from pre-
treated animals as well as in fresh renal cortex slices
to which citrinin was added directly (Table 3). PAH
uptake was depressed significantly, whereas TEA
uptake was either depressed or enhanced, depend-
ing on the dose. The enhanced net uptake of a-
aminoisobutyrate (AIB) transport observed with in
vitro experiments was significant, but minimal
effects on the net accumulation of this amino acid
were observed after pretreatment of rats with
nephrotoxic doses of citrinin.
It is well documented that PAH transport occurs
in the proximal tubule of the kidney [25] and highly
probable that the same is true for TEA [26]. The
effect of citrinin on these transport functions has
provided evidence for a proximal tubular site of ac-
tion. This action does not exclude effects on other
tubule segments. These transport data coupled with
the morphologic studies suggest, however, the
proximal site to be a primary one.
Ochratoxin A also has effects on renal tubular
transport in the rat (Table 3). Multiple, small doses
of ochratoxin caused reductions in PAH and TEA
accumulation with variable effects on NMN and
AIB. With in vitro studies, increasing concentra-
tions of ochratoxin A (10-i to l0 M) caused pro-
gressive inhibition of net organic ion uptake. Maxi-
mal effects are presented in Table 3.
Although the effects of citrinin and ochratoxin on
renal function and transport are not identical in
every respect, there are interesting similarities. Both
substances enhance protein and glucose excretion.
Both substances reduce urine osmolality, although
clearcut effects on urine volume are evident only
with citrinin. Both substances have marked effects
on PAH transport which are more consistent than
those on the transport of other organic compounds,
especially when PAH transport is stimulated by lac-
tate.
The major differences that exist in the effects pro-
duced by these two mycotoxins may relate to their
Table 3. Effect of citrinin or ochratoxin A on the transport of
organic substances by rat renal slices°
Citrinin Ochratoxin A
Pretreatment:
PAH 46 29
PAH with lactate 44 24
TEA 46 66
AIB 98 100
In vitro:
PAH 68 24
PAH with lactate 50 28
TEA 66 76
AIB 123 80
a Experiments were performed at 25° C in the presence of
100% oxygen. All values presented as percent of control. Pre-
treatment doses were: citrinin, 70 mg/kg; ochratoxin A, 2.0 mg/
kg. The citrinin was administered once and the experiments per-
formed 4 days later; ochratoxin A was administered daily for 6
days and the experiments performed 24 hours after the last dose.
For the in vitro experiments, each toxin was used in a concentra-
tionof5 X l05M.
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different pharmacokinetic characteristics. Certainly
a cumulative effect of citrinin would be hard to dem-
onstrate given its relatively rapid clearance even in
the presence of compromised renal function. Stud-
ies by Jordan et al in mice [19] and in our laboratory
in rats (unpublished observations) demonstrated
that repeated, low doses of citrinin did not produce
nephrotoxicity, observations consistent with the
lack of accumulation of citrinin. On the other hand,
repeated doses of ochratoxin A were essential to
produce an alteration of renal function, that is, a
cumulative action was needed before any overt tox-
icologic effect was noted. Apparently citrinin
caused an effect which was self-sustained after citri-
nm was eliminated. With ochratoxin A, either high
levels or the continued presence of the toxin was
needed before disruption of renal function was ob-
served.
Effects of mycotoxins on nonprotein sulfhydryl groups
In an effort to localize a mechanism of action re-
lated to the nephrotoxic effects of these com-
pounds, we examined the effects of citrinin and
ochratoxin A on renal and liver nonprotein sulfhy-
dryl groups. Ninety percent or more of these are
accounted for by glutathione (GSH). Citrinin pro-
duced a biphasic effect on renal GSH. Two to four
hours after administration of a dose of citrinin, renal
GSH fell significantly. Over the next several days,
the tissue concentrations rose to normal, and by 4
days, significantly above normal. Hence, through-
out the period when nephrotoxicity was observed
after a single dose of citrinin (4 to 96 hours), tissue
GSH concentrations were 30 to 40% above normal
(Fig. 4). These data might suggest that the nephro-
toxicity is unrelated to kidney concentrations of the
nonprotein sulfhydryl groups. Liver GSH, although
depressed initially, did not overshoot several days
after pretreatment. Similarly, pretreatment of ani-
mals with ochratoxin A on a schedule of repeated-
doses had only modest effects on renal GSH (that
is, about 20% decrease at 24 hours). Decreased con-
centrations of GSH were observed in the liver late
in the pretreatment regimen, approximately at the
time when alterations in renal function occurred. At
this time, renal GSH, however, was normal.
Although one might argue that the GSH data are
inconsistent with the nephrotoxicity data, there
may be other explanations. With both substances
the occurrence of nephrotoxicity when renal GSH
was normal may be consistent with the production
of an early insult. That is, the toxic effect occurred
early when GSH was reduced and was sustained
(citrinin) or manifested later (ochratoxin) because
of some seif-replicative process within the tissue.
This then would be an effect similar to that ob-
served with carbon tetrachloride hepatotoxicity or
the effects of other halogenated hydrocarbons [27,
28]. Preliminary experiments (Berndt and Hayes,
unpublished observation) indicate "covalent" bind-
ing of carbon 14 in renal tissue after administration
of 14C-citrinin. This observation is consistent with
the production of an early insult.
Another consideration relates to the magnitude of
the effects produced by either citrinin or ochratoxin
A on tissue glutathione. These effects were well be-
low those observed with other nephrotoxic or he-
patotoxic substances. For instance, large doses of
acetaminophen (paracetamol) produced an 80 to
90% reduction in liver and/or renal glutathione con-
centrations [29], and bromobenzene produced an
80% reduction in the liver content of GSH [30]. Nei-
ther citrinin nor ochratoxin A caused reductions of
those magnitudes.
Other possible complications may relate to the
metabolism of citrinin (and possibly ochratoxin A)
and citrinin' s interaction with glutathione to form
conjugates. Although metabolites of citrinin have
been observed in the rat, specific chemical identifi-
cation of these is lacking. Few if any studies have
been undertaken on the metabolism and disposition
of ochratoxin A.
Control
Liver £
Kidney •
Citrinin
(55 mg/Kg)
£
0
8 I
AI
U,
I
4.
43
Days after pretreatment
Fig. 4. Time course of changes in hepatic and renal nonprotein
sulfliydrvl groups (GSH) after citrinin pretreatment. Each sym-
bol is the mean of 4 animals, and the bars are standard errors.
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Experiments with anesthetized rats have been
conducted to examine the metabolism of citrinin
with high-performance liquid chromatography
(HPLC) (Phillips et al, in preparation). Within 10
mm of the administration of citrinin to an anesthe-
tized rat, a metabolite appeared in the blood. By 60
mm after the administration of a large dose (50 mgI
kg) of citrinin, two metabolites appeared in the
urine as well as in the bile. These metabolites com-
prised a major fraction of the administered dose of
citrinin (as much as 40% of the compound excreted
in the urine).
The chemical nature of these metabolites is un-
clear at this time. Chloroform extraction proce-
dures, which allowed extraction of 80 to 90% of au-
thentic citrinin from an aqueous medium, showed
that urine samples obtained from rats that received
large doses of citrinin yielded only 60 to 70% of the
label as carbon trichloride soluble. Hence, 30 to
40% of the labeled material had a higher aqueous
solubility than did authentic citrinin. Incubation of
urine samples with either glucuronidase or sulfatase
failed to improve the carbon-trichloride-extract-
ibility of these urine samples. These data indicate
that the polar-labeled compounds in the urine were
not glucuronide or sulfate conjugates.
It is likely that the urinary metabolites were con-
jugates of citrinin with glutathione or breakdown
products of such a conjugation. This specula-
tion would be consistent with the changes observed
in the tissue glutathione concentrations, at least
early after administration of citrinin. Rapid elimina-
tion of citrinin from plasma was observed, with
blood levels of 14C-citrinin representing only about
1 to 2% of the administered dose by 12 hours after
administration. This agrees approximately with a
decrease in tissue GSH (below control at 4 and 24
hours) and the tendency for recovery of these sulf-
hydryls by 48 hours. Indeed, essentially complete
recovery of GSH by 72 hours is consistent with the
observation that virtually all of the administered cit-
rinin was eliminated by this time. Hence, given that
the urinary metabolites may represent glutathione
or mercapturic acid conjugates, the changes in GSH
noted with citrinin administration may represent
renal mechanisms for elimination of the toxin.
Further, the proposed conjugative reaction may
represent a protective effect of glutathione. That is,
the soluble sulfhydryl substances served as scav-
angers for appropriate reactive compounds, thus
sparing critical macromolecular sulfhydryl groups.
In any event, the indirect evidence suggested that
citrinin was metabolized to a large extent by the rat
and that a likely metabolite was a glutathione or
mercapturic acid conjugate.
The role of the elevated GSH in the kidney 72 to
96 hours after administration of citrinin is unclear.
Such an effect would be consistent with inhibition
of the glutathione peroxidase. This enzyme may be
more important in some tissues than is catalase as a
catalyst for the decomposition of hydrogen per-
oxide [31]. Conceivably, an inhibition of glutathione
peroxidase could result in elevated tissue gluta-
thione. Direct measurements indicated, however,
that glutathione peroxidase activity was increased
rather than decreased at a time when the tissue
GSH were elevated. Indeed, pretreatment of rats
with large doses of glutathione that elevated renal
GSH suggested that enhanced peroxidase activity
was in response to the elevated glutathione concen-
trations (unpublished observations).
Another explanation for the elevated level of
GSH might be enhanced synthesis. Direct measure-
ments of GSH synthesis have not been done. An
inhibition of cysteine dioxygenase by citrinin, how-
ever, may lead to elevated cellular levels of cysteine
(the probable rate-limiting substrate in GSH syn-
thesis), which might promote enhanced glutathione
synthesis. Certainly tissue levels of cysteine are
lower than the concentrations of the other reactants
involved in glutathione synthesis, and cysteine di-
oxygenase is thought to convert cysteine to cys-
teine sulfinic acid, a reaction that helps maintain
cysteine tissue concentrations at their low values.
Because of variations in the designs in the labora-
tory experiments compared with human or animal
experiences in the field, direct comparisons be-
tween literature case reports of animal or human
diseases 1110, 32] and laboratory data seem in-
appropriate. Although involvement of fungal toxins
in animal and human diseases may require "admin-
istration" of the compound or compounds at rela-
tively low doses over very long periods of time, this
is not necessarily the case. For example, the "Sas-
soon Hospital disease" [33] appeared to be an acute
intoxication, and the signs and symptoms not unlike
those reported in our laboratory studies with rats.
Indeed, both qualitative and quantitative changes in
renal function parameters substantiate the com-
parison between laboratory studies and human or
animal diseases. Further, pharmacokinetic data for
citrinin in the rat suggest that cumulative effects of
low doses "administered" chronically are unlikely
to occur. With other substances such as ochratoxin
A, however, chronic, low-dose administration over
long periods of time are essential.
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Preliminary studies presently underway (Hayes
and Berndt, unpublished observations) suggest the
possibility of potentiation of the effect of one of
these fungal toxins by the other. In vitro studies on
renal transport indicated that it was possible to
show inhibitory effects of combined doses of citri-
nm and ochratoxin A at concentrations that were
ineffective when added alone. For example, al-
though no inhibition of PAH transport was ob-
served with a concentration of citrinin or ochrato-
xin A, the combination at these ineffective concen-
trations produced significant effects on PAH
uptake. Although daily administration of citrinin
and ochratoxin A at threshold doses alone and in
combination produced relatively modest effects on
overall renal function, effects were observed on
renal transport studied in vitro with the tissues re-
moved from these pretreated animals. No reduc-
tions in transport were observed with citrinin (10
mg/kg) administered daily for 6 days, and only bor-
derline effects were observed with ochratoxin A
(0.4 mg/kg, 6 days). Animals treated with both citri-
nm and ochratoxin A also showed minimal effects
on overall renal function. A dramatic reduction in
the accumulation of PAH was observed, however.
These data substantiated the possibility of myco-
toxin potentiation as an important factor in the pro-
duction of a Balkan-like syndrome. Furthermore,
observations of this sort suggested the necessity of
a very low dose and long-term administration or
feeding experiments to establish the possible poten-
tiation effects of naturally occurring contaminants
such as fungal toxins not only on renal function but
on hepatic and central nervous system function as
well.
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